Janssen Daalen, Jules M.
Meinders, Marjan J.
Mathur, Soania
van Hees, Hieronymus W.H.
Ainslie, Philip N.
Thijssen, Dick H.J.
Bloem, Bastiaan R.
Funding for this research was provided by:
Michael J. Fox Foundation for Parkinson’s Research (MJFF-019201, MJFF-019201, MJFF-019201, MJFF-019201, MJFF-019201)
Article History
Received: 2 April 2024
Accepted: 31 May 2024
First Online: 22 June 2024
Declarations
:
: The study will be performed according to the guidelines stated in the ‘Declaration of Helsinki’ from 2013 and ‘the Medical Research Involving Human Subjects Act (WMO)’ of the Civil Code of the Netherlands. This study has been reviewed and approved by the Medical Research Ethics Committee East Netherlands, The Netherlands, (reference number NL.83301.091.23) and has been registered at clinicaltrials.gov (NCT05948761, registered June 20th, 2023). Participants receive verbal and written information about the study and written informed consent will be obtained before screening. Participants are covered by trial insurance issued specifically for this study by Radboud University Medical Center.
: Not applicable.
: Bastiaan R. Bloem has received honoraria from serving on the scientific advisory board for Abbvie, Biogen, UCB, and Walk with Path; has received fees for speaking at conferences from AbbVie, Zambon, Roche, GE Healthcare, and Bial; and has received research support from The Netherlands Organisation for Scientific Research, the Michael J. Fox Foundation, UCB, Abbvie, the Stichting Parkinson Fonds, the Hersenstichting Nederland, the Parkinson Foundation, Verily Life Sciences, Horizon 2020, the Topsector Life Sciences and Health, and the Parkinson Vereniging. The other authors have nothing to disclose.